Drugs / danusertib
danusertib
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00872300 | Oct 2008 → Sep 2009 | plasma cell myeloma | Nerviano Medical Sciences | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00766324 | Sep 2007 → Mar 2011 | hormone-resistant prostate carcinoma | Nerviano Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00335868 | Mar 2007 → Dec 2009 | leukemia | Jonsson Comprehensive Cancer Center | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | danusertib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00335868 ↗ |
| Known as | DANUSERTIB (PHA-739358) | ChEMBL registry synonym — accepted as the source's own label CHEMBL402548 ↗ |
| Known as | PHA-739358 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00766324 ↗ |
| Modality | Small molecule | — CHEMBL402548 ↗ |
| Route | Intravenous | “administered as IV infusion” NCT00766324 ↗ |